Wake Forest University Health Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).
Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.
Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,140 total, page 21 of 23
A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
NCT01049243
Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain
NCT00869245
Rapid Administration of Insulin in Sepsis
NCT00823108
Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)
NCT00956501
Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism
NCT00848731
Comparison of Three Cannulas for Hysterosalpingography
NCT00956774
High Dose Vitamin D for Sickle Cell Disease
NCT01331148
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
NCT00863330
Nipple Sparing Mastectomy - Cosmetic Outcomes
NCT01002014
Early Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients
NCT00846352
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
NCT00865774
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
NCT00763035
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
NCT00634582
Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux
NCT01091805
Sexual Absorption of Vaginal Progesterone
NCT01959464
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
NCT00855309
Examining the Relationship Between Hormone Therapy (HT) and Cognitive Function (The WHIMS-ECHO Study)
NCT00745056
American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL
NCT00752895
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
NCT00956488
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00721513
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
NCT01948102
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
NCT00804245
Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer
NCT00743236
Aerobic Exercise in Patients Receiving Chemotherapy for Cancer
NCT00728429
Seniors Health and Activity Research Program-Pilot
NCT00688155
Clot Dissolving Treatment for Blood Clots in the Lungs
NCT00680628
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
NCT00637897
Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast
NCT00665782
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
NCT00601913
Acute Neurobehavioral Program for Improving Functional Status After TBI
NCT01166386
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
NCT00573989
Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression
NCT00621751
Sex Differences in Vascular Markers of Stroke Risk
NCT00681681
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
NCT00369785
Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain
NCT00678639
Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid
NCT00558233
The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients
NCT00660127
Using Beta Blockers to Treat Mitral Regurgitation
NCT00700947
Management of Coccydynia: A Prospective, Observational Study of Coccygectomy
NCT02701192
Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury
NCT00628446
Healthy Living Partnership to Prevent Diabetes
NCT00631345
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01557959
Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
NCT00554489
Using Magnetic Resonance Imaging to Predict People Who Are Likely to Develop Flash Pulmonary Edema (The PREDICT Study)
NCT00542503
Muscadine Grape Seed Supplementation and Vascular Function
NCT01011517
Physical and Mental Assessment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00499785
Non-invasive Blood Pressure (BP) Monitoring Compared to A-Line BP Monitoring
NCT00739700
L-Arginine Supplements in Treating Women Who Are Cancer Survivors
NCT00459134
Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00499447
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
NCT00899197
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 96 |
| Phase 2 | 143 |
| Phase 3 | 31 |
| Phase 4 | 80 |
Therapeutic Areas
What is open in the Wake Forest University Health Sciences pipeline
174 recruiting of 1,140 indexed (15% open); 724 completed (64%).
Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Wake Forest University Health Sciences: open-pipeline peers nationwide
Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,140 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- University of Florida · 1,106 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
Related
What to do with this Wake Forest University Health Sciences page
1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.
- 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.